Wells Fargo analyst Derek Archila raised the firm’s price target on Argenx (ARGX) to $741 from $723 and keeps an Overweight rating on the shares. The firm believes Vyvgart’s sales momentum will continue in 2025, and sees the potential for modest upside to estimates. Further, a handful of smaller clinical catalysts could offer upside but will also improve the narrative around Argenx’s ex-Vyvgart pipeline, Wells adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $720 from $717 at H.C. Wainwright
- Argenx Se: Promising Outlook with Vyvgart Momentum and Pipeline Expansion Justifies Buy Rating
- Argenx Reports Strong 2024 Financial Results and Strategic Growth
- Argenx Se: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
- Argenx’s VYVGART Franchise Drives Strong Performance and Growth Prospects